Klisyri (Tirbanibulin)

Tirbanibulin blocks Src family kinases and interferes with tubulin polymerisation in abnormal keratinocytes. This dual inhibition halts cell‑cycle progression and induces programmed cell death, leading to the removal of dysplastic skin cells that characterize actinic keratosis.

The dosing regimen for Klisyri is determined by the prescribing clinician based on the product’s labeling and the patient’s specific condition. Healthcare professionals select the appropriate amount, frequency, and duration of application.

The pregnancy category for tirbanibulin is unknown. Klisyri should only be used during pregnancy or lactation if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Klisyri, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Klisyri’s tirbanibulin offers a short‑course, topical approach that directly targets Src kinases, whereas alternatives such as 5‑fluorouracil or imiquimod act through different mechanisms like DNA synthesis inhibition or immune modulation. Clinical data suggest comparable efficacy with a distinct safety profile focused on local skin reactions.

Klisyri should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the stability and potency of the 1 % tirbanibulin solution.

Klisyri is applied topically to the affected skin area as directed by a healthcare professional. The solution is spread thinly over each actinic keratosis lesion, ensuring even coverage while avoiding surrounding healthy skin.

Serious risks include severe allergic reactions such as anaphylaxis, extensive skin ulceration, and persistent erythema that may indicate a deeper tissue injury. Patients should seek immediate medical attention if they experience symptoms like swelling, blistering, or systemic signs of hypersensitivity.

Klisyri is contraindicated in individuals with a known hypersensitivity to tirbanibulin or any formulation components. It should also be avoided on compromised skin, open wounds, mucous membranes, and in patients where the risk of severe local irritation outweighs the therapeutic benefit.